129 related articles for article (PubMed ID: 26679149)
1. Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.
de Andrade Pereira B; Maduro Bouillet LE; Dorigo NA; Fraefel C; Bruna-Romero O
PLoS One; 2015; 10(12):e0145260. PubMed ID: 26679149
[TBL] [Abstract][Full Text] [Related]
2. Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?
Fausther-Bovendo H; Kobinger GP
Hum Vaccin Immunother; 2014; 10(10):2875-84. PubMed ID: 25483662
[TBL] [Abstract][Full Text] [Related]
3. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
4. A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55.
Liu T; Zhou Z; Tian X; Liu W; Xu D; Fan Y; Liao J; Gu S; Li X; Zhou R
Vaccine; 2018 Apr; 36(16):2199-2206. PubMed ID: 29548605
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
6. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
Singh S; Vedi S; Li W; Samrat SK; Kumar R; Agrawal B
Vaccine; 2014 May; 32(23):2712-21. PubMed ID: 24631092
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.
He Q; Mao Q; An C; Zhang J; Gao F; Bian L; Li C; Liang Z; Xu M; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):629-637. PubMed ID: 33691606
[TBL] [Abstract][Full Text] [Related]
8. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
9. Generation of protective immune responses against coxsackievirus B3 challenge by DNA prime-protein boost vaccination.
Lan J; Gao Z; Xiong H; Chuai X; Jin Y; Li J; Xian X; Liu G; Xie L; Zhang Y; Wang Y
Vaccine; 2011 Sep; 29(40):6894-902. PubMed ID: 21803097
[TBL] [Abstract][Full Text] [Related]
10. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
[TBL] [Abstract][Full Text] [Related]
11. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
12. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier.
Xiang ZQ; Yang Y; Wilson JM; Ertl HC
Virology; 1996 May; 219(1):220-7. PubMed ID: 8623532
[TBL] [Abstract][Full Text] [Related]
13. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55.
Tian X; Jiang Z; Fan Y; Qiu S; Zhang L; Li X; Zhou Z; Liu T; Ma Q; Lu X; Zhong B; Zhou R
Antiviral Res; 2018 Jun; 154():17-25. PubMed ID: 29626491
[TBL] [Abstract][Full Text] [Related]
15. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
[TBL] [Abstract][Full Text] [Related]
16. Two replication-defective adenoviral vaccine vectors for the induction of immune responses to PPRV.
Rojas JM; Moreno H; García A; Ramírez JC; Sevilla N; Martín V
Vaccine; 2014 Jan; 32(3):393-400. PubMed ID: 24269622
[TBL] [Abstract][Full Text] [Related]
17. Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.
Huret C; Desjardins D; Miyalou M; Levacher B; Amadoudji Zin M; Bonduelle O; Combadière B; Dalba C; Klatzmann D; Bellier B
Vaccine; 2013 Mar; 31(11):1540-7. PubMed ID: 22634300
[TBL] [Abstract][Full Text] [Related]
18. Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination.
Holst PJ; Ørskov C; Thomsen AR; Christensen JP
J Immunol; 2010 Apr; 184(8):4431-9. PubMed ID: 20212099
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
[TBL] [Abstract][Full Text] [Related]
20. Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.
Goffin E; Javaux J; Destexhe E; Pretto CD; Spindler KR; Machiels B; Gillet L
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
